Helix BioPharma Expands Portfolio with Key Acquisition

Helix BioPharma (TSE:HBP) has released an update.

Helix BioPharma Corp. has entered into an asset purchase agreement to acquire an oral immune checkpoint inhibitor from Laevoroc Immunology AG, enhancing its immune-oncology portfolio. This transaction will involve issuing 16.5% of Helix’s shares to acquire intellectual property and assets, pending regulatory approval. The move aims to expand Helix’s pipeline with promising therapeutic candidates for leukemia patients.

For further insights into TSE:HBP stock, check out TipRanks’ Stock Analysis page.